Risk Stratification of COVID-19 Using Urine Biomarkers

This study will conduct to elucidate the following clinical question; 1. if the single urinary biomarker or the combination of urinary biomarkers will clarify the risk of COVID-19 confirmed mild cases. These biomarkers must be warranted to clinical use based on the evaluation by either CE or PMDA or FDA. Examination should be done within 72 h after the start of COVID-19. 2. if above addressed biomarker can classify the effectiveness of therapy directed to COVID-19.